Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label previous answer version answering member constituency answering member printed answering member label
tabling member	label

Search

1201808

	registered interest
	date	09/06/2020
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Breast Cancer: Medical Treatments
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what steps he is taking to ensure that people with incurable secondary breast cancer may receive timely treatment in covid-19 free hubs and sites.
	tabling member constituency	North Warwickshire
	tabling member printed	Craig Tracey
	uin	57300
	answer	answer is ministerial correction date of answer 01/07/2020 answer text <p>NHS England and NHS Improvement have put in place arrangements to ensure that essential and urgent treatment for cancers has continued throughout the response to the pandemic, including issuing clear guidance to the system and supporting the development of cancer ‘hubs’ for surgery. This is dependent on the advice of clinicians, who will consider the possible risks and with patient safety at core of the decision making process.</p><p>The National Health Service is now working to restore and recover all cancer services, including for people with secondary breast cancer, in ways that keep patients as safe as possible.</p> answering member constituency Bury St Edmunds answering member printed Jo Churchill question first answered 01/07/2020 16:46:16 answering member 4380 label Biography information for Jo Churchill
	tabling member	4509 label Biography information for Craig Tracey

1232429

	registered interest
	date	08/09/2020
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Breast Cancer: Health Services
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what steps his Department is taking to reduce the backlog of breast cancer surgeries, treatments and screenings resulting from the covid-19 outbreak.
	tabling member constituency	North Warwickshire
	tabling member printed	Craig Tracey
	uin	86715
	answer	answer is ministerial correction date of answer 05/11/2020 answer text <p>The National Health Service is restoring the full operation of all cancer services, with local delivery plans being delivered by Cancer Alliances.</p><p>Systems will work with general practitioners and the public locally to restore the number of people coming forward and being referred with suspected cancer to at least pre-pandemic levels.</p><p>Sufficient diagnostic capacity in COVID-19 secure environments will be supplied through the use of independent sector facilities, the development of Community Diagnostic Hubs and Rapid Diagnostic Centres, further all cancer screening programmes will be fully restarted.</p> answering member constituency Bury St Edmunds answering member printed Jo Churchill question first answered 05/11/2020 15:45:36 answering member 4380 label Biography information for Jo Churchill
	tabling member	4509 label Biography information for Craig Tracey

1232431

	registered interest
	date	08/09/2020
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Breast Cancer: Screening
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, with reference to the article published in The Lancet on 12 August 2020 entitled Effect of mammographic screening from age 40 years on breast cancer mortality, if his Department will make an assessment of the potential merits of lowering the breast cancer screening age for women.
	tabling member constituency	North Warwickshire
	tabling member printed	Craig Tracey
	uin	86716
	answer	answer is ministerial correction date of answer 22/09/2020 answer text <p>The United Kingdom National Screening Committee (UK NSC) is aware of the The Lancet publication of the long-term outcomes of the UK Breast Screening Age trial.</p><p>The UK NSC will examine the findings carefully along with other initiatives in this area, which includes the use of artificial intelligence and digital pathology in the National Health Service Breast Screening Programme (NHS BSP). Currently there is a robust estimate that the current NHS BSP strategy is effective in preventing deaths from breast cancer. This involves regular screening in women aged 50 up to their 71<sup>st</sup> birthday.</p><p>The UK NSC also awaits the publication of the Age Extension Trial of screening in women over the age of 70 which is due to report in 2026.</p><p>The Committee’s overriding concern is that any significant change to the Programme should result in more good than harm and be cost proportionable.</p><p> </p> answering member constituency Bury St Edmunds answering member printed Jo Churchill question first answered 22/09/2020 08:44:00 answering member 4380 label Biography information for Jo Churchill
	tabling member	4509 label Biography information for Craig Tracey

1171026

	registered interest
	date	15/01/2020
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Cannabis: Medical Treatments
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, whether there are circumstances under which Specialist Importers of cannabis-based products for medicinal use are permitted to import that product in bulk.
	tabling member constituency	Reigate
	tabling member printed	Crispin Blunt
	uin	3661
	answer	answer is ministerial correction date of answer 24/01/2020 answer text <p>Unlicensed cannabis-based products for medicinal use (CBPM) may only be imported to meet the special clinical need of individual patients. It is not currently possible to import bulk quantities of these products. This restriction forms part of the checks and balances that the Advisory Council on the Misuse of Drugs asked the Government to put in place when rescheduling CBPMs to minimise the risk of misuse and diversion.</p><p>The Medicines and Healthcare products and Regulatory Agency has received 242 notifications for the importation of unlicensed CBPMs from specialist importers in the past 12 months.</p><p>Unlicensed medicines, including CBPMs are not assessed by the MHRA for quality, safety and efficacy, but must be notified to the MHRA prior to import and meet basic production standards.</p><p>Importers registered with the MHRA can import active pharmaceutical ingredients where intended for the production of a medicinal product for use in humans.</p><p> </p> answering member constituency Bury St Edmunds answering member printed Jo Churchill grouped question UIN 3662 3663 3664 question first answered 24/01/2020 14:53:45 answering member 4380 label Biography information for Jo Churchill
	tabling member	104 label Biography information for Crispin Blunt

1171027

	registered interest
	date	15/01/2020
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Cannabis: Medical Treatments
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, how many notifications the Medicines and Healthcare products Regulatory Agency has received from (a) pharmacies and (b) Specialist Importers on importation orders for unlicensed cannabis-based products for medicinal use in the last 12 months.
	tabling member constituency	Reigate
	tabling member printed	Crispin Blunt
	uin	3662
	answer	answer is ministerial correction date of answer 24/01/2020 answer text <p>Unlicensed cannabis-based products for medicinal use (CBPM) may only be imported to meet the special clinical need of individual patients. It is not currently possible to import bulk quantities of these products. This restriction forms part of the checks and balances that the Advisory Council on the Misuse of Drugs asked the Government to put in place when rescheduling CBPMs to minimise the risk of misuse and diversion.</p><p>The Medicines and Healthcare products and Regulatory Agency has received 242 notifications for the importation of unlicensed CBPMs from specialist importers in the past 12 months.</p><p>Unlicensed medicines, including CBPMs are not assessed by the MHRA for quality, safety and efficacy, but must be notified to the MHRA prior to import and meet basic production standards.</p><p>Importers registered with the MHRA can import active pharmaceutical ingredients where intended for the production of a medicinal product for use in humans.</p><p> </p> answering member constituency Bury St Edmunds answering member printed Jo Churchill grouped question UIN 3661 3663 3664 question first answered 24/01/2020 14:53:45 answering member 4380 label Biography information for Jo Churchill
	tabling member	104 label Biography information for Crispin Blunt

1171028

	registered interest
	date	15/01/2020
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Cannabis: Medical Treatments
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, whether the Medicines and Healthcare products Regulatory Agency has assessed the (a) safety and (b) quality of unlicensed cannabis-based products for medicinal use.
	tabling member constituency	Reigate
	tabling member printed	Crispin Blunt
	uin	3663
	answer	answer is ministerial correction date of answer 24/01/2020 answer text <p>Unlicensed cannabis-based products for medicinal use (CBPM) may only be imported to meet the special clinical need of individual patients. It is not currently possible to import bulk quantities of these products. This restriction forms part of the checks and balances that the Advisory Council on the Misuse of Drugs asked the Government to put in place when rescheduling CBPMs to minimise the risk of misuse and diversion.</p><p>The Medicines and Healthcare products and Regulatory Agency has received 242 notifications for the importation of unlicensed CBPMs from specialist importers in the past 12 months.</p><p>Unlicensed medicines, including CBPMs are not assessed by the MHRA for quality, safety and efficacy, but must be notified to the MHRA prior to import and meet basic production standards.</p><p>Importers registered with the MHRA can import active pharmaceutical ingredients where intended for the production of a medicinal product for use in humans.</p><p> </p> answering member constituency Bury St Edmunds answering member printed Jo Churchill grouped question UIN 3661 3662 3664 question first answered 24/01/2020 14:53:45 answering member 4380 label Biography information for Jo Churchill
	tabling member	104 label Biography information for Crispin Blunt

1171029

	registered interest
	date	15/01/2020
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Cannabis: Medical Treatments
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, whether there are circumstances under which Specialist Importers may import cannabis-based active pharmaceutical ingredients for use in the manufacturing of cannabis-based products for medicinal use in the UK.
	tabling member constituency	Reigate
	tabling member printed	Crispin Blunt
	uin	3664
	answer	answer is ministerial correction date of answer 24/01/2020 answer text <p>Unlicensed cannabis-based products for medicinal use (CBPM) may only be imported to meet the special clinical need of individual patients. It is not currently possible to import bulk quantities of these products. This restriction forms part of the checks and balances that the Advisory Council on the Misuse of Drugs asked the Government to put in place when rescheduling CBPMs to minimise the risk of misuse and diversion.</p><p>The Medicines and Healthcare products and Regulatory Agency has received 242 notifications for the importation of unlicensed CBPMs from specialist importers in the past 12 months.</p><p>Unlicensed medicines, including CBPMs are not assessed by the MHRA for quality, safety and efficacy, but must be notified to the MHRA prior to import and meet basic production standards.</p><p>Importers registered with the MHRA can import active pharmaceutical ingredients where intended for the production of a medicinal product for use in humans.</p><p> </p> answering member constituency Bury St Edmunds answering member printed Jo Churchill grouped question UIN 3661 3662 3663 question first answered 24/01/2020 14:53:45 answering member 4380 label Biography information for Jo Churchill
	tabling member	104 label Biography information for Crispin Blunt

1251561

	registered interest
	date	12/11/2020
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Psilocybin
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, with reference to the letter of 16 October 2020 from the Minister with responsibility for drugs to the hon. Member for Reigate, what assessment he has made of the implications for his policies of emerging evidence on the use of Psylocybin in the treatment of depression and trauma.
	tabling member constituency	Reigate
	tabling member printed	Crispin Blunt
	uin	114744
	answer	answer is ministerial correction date of answer 14/01/2021 answer text <p>The Government has made no recent assessment of the potential merits of rescheduling psilocybin, which remains a Schedule 1 substance under the Misuse of Drugs Regulations 2001 (the 2001 Regulations).</p><p>Ministers continue to take a close interest in any new evidence relating to controlled drugs and they would seek expert advice from the Advisory Council on the Misuse of Drugs before making any amendments to the 2001 Regulations.</p> answering member constituency Bury St Edmunds answering member printed Jo Churchill question first answered 14/01/2021 15:59:51 answering member 4380 label Biography information for Jo Churchill previous answer version 62013 answering member constituency Bury St Edmunds answering member printed Jo Churchill answering member 4380 label Biography information for Jo Churchill
	tabling member	104 label Biography information for Crispin Blunt

1330234

	registered interest
	date	07/06/2021
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Alcoholic Drinks and Tobacco: Misuse
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what recent assessment he has made of (a) the likelihood of alcohol and tobacco being misused, (b) the risk of alcohol and tobacco misuse causing harmful effects sufficient to constitute a social problem and (c) the effectiveness of excluding alcohol and tobacco from control of harmful drugs under the Misuse of Drugs Act 1971.
	tabling member constituency	Reigate
	tabling member printed	Crispin Blunt
	uin	11460
	answer	answer is ministerial correction date of answer 10/06/2021 answer text <p>No recent assessment has been made.</p><p>The Government is committed to supporting the most vulnerable at risk from alcohol misuse, including through establishing alcohol care teams in hospitals and supporting children of alcohol dependent parents. We will be publishing a new Tobacco Control Plan later this year setting out plans for England to become a smoke-free country by 2030.</p> answering member constituency Bury St Edmunds answering member printed Jo Churchill question first answered 10/06/2021 11:51:01 answering member 4380 label Biography information for Jo Churchill
	tabling member	104 label Biography information for Crispin Blunt

1332261

	registered interest
	date	11/06/2021
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	European Monitoring Centre for Drugs and Drug Addiction
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what risk assessment he has made of the implications of ending UK participation with the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) European Drug Report 2021; and on what basis the UK Government has withdrawn from participation, in the context of EU membership not being a requirement.
	tabling member constituency	Reigate
	tabling member printed	Crispin Blunt
	uin	14130
	answer	answer is ministerial correction date of answer 18/06/2021 answer text <p>In line with the Withdrawal Agreement, the United Kingdom ceased to be a member of the European Monitoring Centre for Drugs and Drug Addition (EMCDDA) on 31 January 2020. As the UK is no longer a member of EMCDDA, it does not take part in the annual reporting process.</p><p>The UK continues to have strong domestic drugs monitoring and surveillance systems, augmented through our sharing of information and expertise with international partners, including the United Nations Office on Drugs and Crime and the World Health Organization.</p> answering member constituency Bury St Edmunds answering member printed Jo Churchill question first answered 18/06/2021 09:21:51 answering member 4380 label Biography information for Jo Churchill previous answer version 6939 answering member constituency Bury St Edmunds answering member printed Jo Churchill answering member 4380 label Biography information for Jo Churchill
	tabling member	104 label Biography information for Crispin Blunt